Good afternoon. I'm Hiromasa Furukawa, CFO of the JT Group. Thank you for joining us today for JT Group's first quarter 2025 earnings briefing. First, I'd like to touch on the transfers of both the pharmaceutical business to Shionogi and the shares of Torii, which we have announced today. JT entered the pharmaceutical business back in 1987 and welcomed Torii as a member of the group in 1998. Over the years, together with Torii, JT built an integrated value chain for the pharmaceutical business, and by maximizing synergies and opportunities, the pharmaceutical business has been providing prescription drugs that are trusted by many patients. The environment surrounding the pharmaceutical business has been changing in recent years. International competition has intensified. Also, joint R&D activities of the pharmaceutical business with external partners have been gradually restricted due to the constraints related to the presence of tobacco products at JT. Based on our assessment, it appears that under the current structure and considering the highlighted environmental changes, the mid to long-term growth outlook of the pharmaceutical business will be uncertain. As a result, we have decided to transfer the pharmaceutical business, including Torii, to Shionogi. Shionogi is a global pharmaceutical company that has grown over the past 140 years by primarily providing prescription drugs. Like JT's pharmaceutical business, it has a strength in original drugs based on small molecules. We believe that this aligns well with JT's pharmaceutical business R&D strategy. In addition, the compound pipeline of both companies has little overlap, creating incremental complementarity across their portfolio. Moreover, Shionogi has a longstanding policy of investing in R&D in a consistent and significant manner. We believe that Shionogi is the best company to transfer the pharmaceutical business and optimize the drug discovery potential and human resources expertise and capabilities. Regarding the financial impact, the profit attributable to owners of the parent company is expected to decrease by approximately JPY 6 billion as a result of these transactions on the consolidated financial results for the fiscal year 2025, as stated in the press release. If this transaction progresses as planned, the pharmaceutical business, including Torii, is expected to be classified as a discontinued operation from the third quarter of fiscal year 2025. The financial impact of JPY 6 billion will be recorded under discontinued operations. As for the dividend for FY 2025, it is determined based on the payout ratio calculated on a continuing operation basis, meaning there will be no impact on the dividend from these transactions. Lastly, there is no change in the strategic roles of the tobacco and processed food businesses. JT will continue to position its tobacco business as a core profit growth driver and its processed food business as a complementary driver of the JT Group's profit growth. JT will strive to achieve the JT Group purpose and deliver sustainable profit growth over the mid to long- term. I'll start with the three-month consolidated financial results. As shown on the slide, revenue and AOP grew strongly, both on a constant effect and on a reported basis, marking a strong start for the year. AOP at a constant effect, our primary performance indicator, increased by an impressive 20.8% year-on- year, driven by the solid contribution from our core tobacco business. The growth in the tobacco business was fueled by pricing in combustibles and the inclusion of Vector Group, which outweighed the higher investment towards Ploom, and inflation-led cost increases, including across our supply chain. The increased profit in the pharmaceutical business also complemented the overall growth. With regard to the foreign exchange impact on AOP, the depreciation of some emerging market currencies and the appreciation of cost-related currencies, such as the U.S. dollar, partially offset the positive impact from the yen depreciation against several currencies. Operating profit increased by 15.3% year-on-year, driven by the AOP increase despite higher cost adjustment items, including higher amortization cost of intangible assets related to the Vector acquisition. Profit was broadly stable year-on-year, as the increasing operating profit was mostly offset by higher financing costs related to the Vector acquisition, as well as higher corporate tax expenses, mainly due to the absence of one-off factors that occurred in the previous year and had lowered the effective tax rate. Moving on to the results of each business segment, starting with the tobacco business. Please see slide five for the volume performance of the tobacco business. Total volume, combining both combustibles and RRP, decreased by 1.3% year-on-year. However, when excluding the unfavorable impact of inventory adjustment, mainly in Russia and Western Europe, total volume actually grew by 0.2% year-on-year. In the combustible category, share momentum continued in many markets alongside the strong volume growth in the EMA cluster. Some of the drivers in EMA included the contribution from the Vector Group acquisition, a resilient industry volume in several markets, including in the key markets of Russia and Turkey, as well as continued growth in the global travel retail. Despite these positive items, overall combustibles volume decreased 1.7% year-on-year due to continued decline in combustible industry volume in Japan, the Philippines, and the U.K., and unfavorable inventory movement. RRP and HTS volume growth partially offset the combustibles decline through a significant year-on-year increase of 19.0% and 27.7%, respectively. In HTS, which is our investment priority, Ploom's segment share steadily increased across the global footprint. Moving on to the financial performance of the tobacco business on slide six. In the first quarter, we delivered another remarkable top line and AOP growth driven by pricing contributions in multiple markets. Focusing on the AOP growth drivers, volume contribution was positively fueled by the inclusion of Vector Group. The volume increase contribution in the high-margin USA market also led to an improved market mix, offsetting the negative impact of the decrease in total volume. The price mix contribution was very strong. Pricing contributions in many markets, including the Philippines, Russia, and the U.K., outweighed the lower product mix, mainly due to downtrading in Japan and the Philippines. These positive factors exceeded the inflation-led cost increases within the supply chain, including tobacco leaf and labor, and incremental investment towards Ploom, resulting in a year-on-year increase of 20.9% in AOP at constant effects. As of today, we have already secured over 80% of the planned pricing in combustibles for FY 2025 through the implemented price increases. Effects impact on AOP was unfavorable, mainly due to depreciation of cost-related currencies such as the U.S. dollar, and the depreciation was certain emerging market currencies despite a weaker yen. AOP in the first quarter, for both reported and at constant effect basis, came in stronger than expected, fueled by the solid organic performance driven by volume and pricing. In addition, the effects impact on our business was less negative due to the favorable movement of certain currencies, including the depreciation of the dollar on our U.S. dollar cost base compared to our full-year forecast. [Foreign language] Slide seven reveals the performance of the three clusters in the tobacco business. The graphs on this slide show year-on-year variances in total volume, core revenue, and AOP at constant effects for each cluster. [Foreign language] Let me start with Asia. This cluster includes the key markets of Japan, the Philippines, and Taiwan. Total volume in this cluster decreased by 2.4% year-on-year, mainly due to lower combustibles industry volume in Japan, the Philippines, and Taiwan, even though partially offset by market share gains in Bangladesh and Taiwan, and higher Ploom volumes in Japan. Regarding financial results, a strong pricing contribution in the Philippines outweighed the negative volume impact and the lower product mix, mainly due to downtrading in Japan and also the Philippines, resulting in higher revenue and AOP. Turning to Western Europe, which includes the key markets of Italy, Spain, and the U.K., total volume decreased by 9.3% year-on-year due to lower combustibles industry volume in several markets, including France and the U.K., as well as unfavorable inventory movements, which exceeded the positive share momentum in several markets. Ploom continued to gain share in the HTS segment, although RRP volume decreased year-on-year. This decrease was due to an unfavorable comparison from the temporary build-up of inventory that occurred during the Ploom promotion activities carried out in various countries in the same period of the previous year. Core revenue and AOP grew as the pricing contributions, mainly in Italy and the U.K., offset the negative volume variance, mainly in the U.K., incremental investments toward Ploom, and inflation-led cost increases, including in the supply chain. Moving on to EMA, this cluster includes the key markets of Romania, Russia, Turkey, and from this year, the USA. Total volume increased by 1.7% year-on-year, driven by the inclusion of the Vector Group, as well as market share gains in several markets, better-than-expected industry volume in Russia and Turkey, and continued growth of global travel retail. The cluster reported an increase in both revenue and AOP at constant effects, driven by the increase of total volume and an improved market mix from the inclusion of Vector Group. In addition, pricing contributions, mainly in Russia and Iran, more than offset the incremental investment towards Ploom and inflation-led cost increases, including in the supply chain. Moving on to slide eight. As shown in the slide, we will be introducing a new Ploom ecosystem this year, starting with Japan. The new ecosystem is composed of a new and improved Ploom device, as well as premium blend heated tobacco sticks. Both were designed and developed based on consumer feedback related to Ploom X and Ploom X Advanced, as well as market research. We will be providing more details at the launch event, which is scheduled on 27th May. Since 2023, Ploom has accelerated its geo-expansion, and I am pleased to report that at the end of February, Ploom grew its share of the HTS segment by 3.6 percentage points since the end of 2022, reaching 8.2%. This achievement keeps us on track to deliver on our ambition to reach mid-teen HTS share by the end of 2028. We are confident that the introduction of the new and improved Ploom ecosystem will further expand our market share, not only in Japan but also in overseas markets. Slide nine provides an update on the HTS share trends of Ploom in selected markets. As shown on the graphs, Ploom's share within the HTS segment is continuing to grow both in and outside Japan. In Japan, HTS share of segment reached 12.7% on the quarterly average in the first quarter, fueled by solid share gains in March, during which Ploom grew to 13.1%. Our share gains are solid and will continue despite continued product launches and intense promotional activities by competitors. Outside of Japan, even though competition is heating up, our HTS share of segment continues to grow steadily. This is driven by the expansion of our distribution networks, leveraging opportunities through partnerships with local events and seasonal campaigns, and our strengthened marketing efforts using digital media and online platforms. Going forward, we will continue to optimize insights gained from each market, as well as feedback from consumers, and strive to enhance the awareness of Ploom to increase its market share through a tailored approach. Next, I will explain the results of the pharmaceutical and processed food businesses, starting with the pharmaceutical business. Revenue increased by JPY 2.0 billion year-on-year due to the sales increase in the area of skin disease and allergen at our subsidiary Torii Pharmaceutical, and increased overseas royalty income from the depreciation of the yen. AOP increased year-on-year due to higher revenue offsetting SG&A expenses. Moving to the processed food business, revenue increased by JPY 0.8 billion year-on-year, driven by the positive impacts from price revisions and the sales growth of packaged cooked rice due to supply shortages of rice in the frozen and ambient food business. AOP decreased mainly due to the higher raw material costs, such as rice, which could not be offset by the higher revenue. In closing, please see slide 12. To summarize the first quarter results, I am pleased to report a great start for 2025. We have achieved strong top line growth driven by the solid pricing contribution in the tobacco business, leading to AOP at constant effects on the consolidated basis, growing by a remarkable 20.8%. In the tobacco business, the business fundamentals came in very strong, with solid market share momentum combined with a more resilient industry volume and robust pricing. Effects also trended positively compared to the initial assumptions, putting us well on track to achieve our full-year forecast. [Foreign language] On the other hand, since April, we have seen increased instability. For instance, the dollar-yen exchange rate has been very volatile, hovering between JPY 139 and JPY 151. In addition, global economic dynamics have evolved in part due to changing tariffs, while geopolitical risks in our EMA cluster continued. We will continue to closely monitor the situation and will update our earnings forecast if and when necessary. Lastly, as a reminder, we will be hosting a launch event for the new and improved Ploom ecosystem on 27th May. Until then, we ask for your patience regarding additional details on the device and the heated tobacco sticks. This concludes my presentation. Thank you very much for your attention. Thank you very much. Now, we'd like to move to Q&A session. Let me introduce you to the speakers for answering your questions today: Hiromasa Furukawa, CFO of the JT Group, and Nobuya Kato, JTI Deputy CEO. Next, I'll show you how to ask questions. We are afraid we do not accept questions in this English line. If you have any question, please send an email to jt.ir@jt.com. We'll introduce your question accordingly. Thank you for your understanding. [Foreign language] Thank you for waiting. The first question comes from Mr. Saji from Mizuho Securities. Thank you. Now, I'd like to ask about the transfer and the pharmaceutical business. At this time, what is rational to make this decision? It might be the competitive environment or the R&D negative impact due to the tobacco business. Why did you make a decision at this timing? If possible, I'd like to know about the cash- in, including the American company. That would be about JPY 80 billion or so. I'd like to know the use of this cash- in. There was an announcement today as a background of the transfer of the pharmaceutical business and the use of the cash in. Mr. Furukawa, take that question. Thank you very much for that question. What is the reason for this timing? Also, the use of the cash was your question. This transaction with Shionogi. As for the timing, as was mentioned in the official document of Shionogi, they are going to make the new healthcare future with a platform. From 2020, they have been considering the possibility of joining hands with us. Based on that, starting from August 2024, there was the move of the proposal of the transfer of our pharmaceutical business and also Torii shares. We have been constantly considering that opportunity. Currently, we have received the proposal from Shionogi. In order to have the further expansion of the pharma business, we thought this would be the best option to achieve that target. Second, the use of cash. We are going to have the cash- in with this transaction. With regard to the use, the final amount is not yet finalized, so I cannot give you the detail at this point of time. Also, about JPY 70 billion cash- in was already announced. With the transfer of the share, Torii's cash and the deposit will be about JPY 30 billion or so, and that needs to be deducted. Our JPY 70 billion will not be the total cash- in. For this amount of cash- in, we are going to be based on the cash allocation. Based on that policy, we would like to make a decision. Currently, we are not thinking about the share repurchase using this proceeds. Thank you. Thank you very much. Thank you very much, Mr. Saji. The next question comes from JP Morgan, Fujiwara-san. Mr. Fujiwara, over to you. Hello. This is Fujiwara of JP Morgan. I have one question about the tobacco business. In the second quarter and beyond, we would like to know what is going to be the forecast on the constant effects base. You're talking about the increase of the profit by about JPY 50 billion. The full-year forecast is about the increase by JPY 64-65 billion. I think about 80% has already been achieved. In the second quarter and beyond, because the industry volume seems to be solid and the pricing was very steady in the first quarter, which is likely to continue for the second quarter and beyond, can we expect that the stronger performance is expected for the second quarter and beyond, or are there any risks that we need to consider and bake in? The question is about the tobacco business, the forecast for the year to go. Kato of JTI Deputy CEO is going to answer. Mr. Fujiwara, thank you for your question. This is Kato speaking. The outlook for the Q2 and beyond is your question. The achievement of the Q1 was very strong. That was partly coming from the acquisition of Vector, but the organic-based business performance was very strong as well. In a nutshell, on the full-year basis, on the 12-month basis, this steady performance in the Q1 is highly able to continue for the rest of the year. That is what we are feeling. As a result, as we showed in the beginning of the year, the target growth that we have shown at the beginning of the year, we are confident to say that that is achievable. That is the general observation. Now, talking about the Q2 and year- to- go, as I said, Q1 was very steady in the growth itself, especially AOP growth rate was over 20%. On the 12-month basis, in Q2 and beyond, especially in Q4 at the end of last year, the Vector acquisition contribution was already factored in. That means the positive impact in Q4 is going to be down over last year. Also, the Ploom new device and the launch of those new products and sets is going to make the progress. That launch and the transition to that new device and the new product will need a sizable amount of investment. Also, talking about the cost for the leaf tobacco, because of the bad weather of last year, the sourcing cost has increased last year. The use of those expensive leaf is going to be happening since the second half of this year. Throughout the 12-month basis, we are confident to achieve the target on the full-year basis, and we think we can show the steady growth. However, the growth rate that we saw in Q1 and compared to that strong growth rate, the magnitude of the growth momentum itself is probably going to be smaller for the second quarter and beyond compared to Q1. Okay. Sure. Please go ahead. Talking about the potential risks, in Q1, the business was very strong, but in the U.K. or the Philippines, there were some repeated taxation and the pricing, so that the total volume has slowed down. It is a bit weaker compared to what we had assumed. It could be a risk going forward, which we need to monitor closely. In the total volume throughout the year, the guidance was shown at the beginning of the year, and we just have it as unchanged. Okay. Thank you very much. One supplement question. The first quarter Vector contribution onto revenue and AOP base, what kind of a contribution were there? Can you give me some quantification? The Vector's contribution, of course, the effect of the acquisition we do not disclose in the particular market or so, but in the qualitative contribution, if I may, in the beginning of the year, we were talking about the AOP growth over the last year. The contribution of Vector is about 4%-5%. That was what we had assumed. In Q1 or throughout the year for 12-month basis, the guidance that we showed is basically being kept. We think we are in line with that expectation. Although we can't give you the pinpoint figure quantitatively, that's what we are assuming to land. So roughly on quarter, that's probably around JPY 10 billion or so, I guess. That's not very far off from the mark, I guess. I can't give you the figure with a quantitative pinpoint figure, but okay. Thank you very much for that. Mr. Fujiwara, thank you very much. Now, I'd like to invite the next question. Mr. Morita from Nomura Securities, please. I'm Morita from Nomura Securities. Again, I'd like to ask about the return to shareholders. You said 75%. And when it was introduced, it was a very competitive level. However, in the last one or two years, looking at the global situations and also Japanese FSCG market or the food companies, they have been enhancing the return to shareholders. Besides dividend, they are looking at the total return, including the return and then 75%. Does not sound so competitive at this point of time. You said that in your message, you are going to show the competitive return to shareholders. How do you see this payout ratio of 75%? Do you have any plan to enhance that further? This question is about the return to shareholders. Furukawa, retake that question. I am Furukawa. Thank you very much for that question. Payout ratio and also our view for the return to shareholders. Constantly, we are trying to be competitive in the capital market. As you have exactly commented at this point of time, a payout ratio is shown as 75% as of a guideline. Also, including our shares buyback, we are looking at the financial situation of the particular year. Mid-term capital demand is also monitored. Actually, as I said at the beginning, what is a competitive level in the capital market? The environment is changing and also our financial conditions and our business are changing. We need to take all of them into consideration. At this point of time, as we have been saying, there is no change of the policy of the return to shareholders. As we have mentioned in our allocation of the management resources, we are going to be conducive to the mid to long-term business growth. We are going to have the balance between the business growth and also the investment and the return to shareholders. We will continue to enhance our business foundation. By increasing or improving our business in the midterm, I would like to enhance the return to shareholders. Thank you for your question. Follow-up question. For confirmation, in the two to three years, excuse me, in the last one or two years, global FMCG companies have been enhancing the return to shareholders. Do you agree? As I said, the competitive level in the capital market, and we cannot give you the detail, but in order to have the right understanding, we have been seeing our competitors in the adjacent industry and also return to shareholders in the various industry and the level have been monitored. We have been taking that into our consideration. Understood. Thank you. Mr. Morita, thank you for your question. The next question comes from Morgan Stanley MUFG Securities, Ms. Miyake. Ms. Miyake, please. Thank you very much. This is Miyake of Morgan Stanley. I also have a question about the organic performance, the business performance. You have a plan, and you have actually outweighed that performance. Also, you had the comment about the second quarter and beyond. I'd like to have a further deep dive. In Q1, you have landed better than your original plan. I think the good contribution was the pricing. The pricing was actually stronger as an impact more than you had thought. Is that right to say? Or because of the taxation, there was some cost merit onto you? Can you have a little bit of the color on that, please? Also, for the second quarter and beyond, the growth rate is probably not going to be as high as the first quarter, you said. Now, Q4 probably seems to go down, well, because of the launch of the Ploom new device, which is going to incur some cost and investment, and also the leaf tobacco cost increase and so on. When you made the original plan, those factors have probably been already baked in, was not they? Can you also clarify which has been already included in the original plan and which were not? I would appreciate that classification. Thank you. Thank you very much for the question. That is about the Q1 result, which had been better than the original assumption. Also, the question for the short-term outlook, Mr. Kato is going to take those questions. Ms. Miyake, thank you for your question. Regarding the organic business performance, including the pricing impact, I would like to give you more specifics about the drivers. As you said, the biggest contribution was the pricing. The pricing was very strong. To be more specific, by region, the Philippines, Russia, U.K., Poland, and Italy, in many markets like that. Since last year, the pricing momentum was very strong. There was some carryover since last fiscal year, in addition to which the pricing was done more than we had anticipated. That delivered a great positive impact. The cost for Q2 and beyond, for the previous questions, I talked about the cost. That is going to be some increase compared to last year. On plan, we had already included those impacts. I was talking about the comparison of the growth rate of this year over the last fiscal year. As we have baked in for the current year, the cost and the investment are going to happen for this year. The growth rate of this year over last year would be slower as a possibility. That is what I mentioned. Now, talking about the pricing, as Furukawa mentioned in the presentation, pricing has been done very strongly. I may be repeating myself, but as of even today, the combustibles pricing impact that we had assumed to happen for the current fiscal year, we have already secured and locked in about 80% against the total plan that we have had for the year. Also, this strong pricing has been driving us to achieve the original targets for the current year. Throughout the plan, the steady growth momentum is going to be kept, is what we are thinking as we stand. Thank you so much. In the original plan, you were talking about Russia and Turkey. Probably those markets might have some potential risks of the slowdown of the business. In the second quarter, can we understand that it's not really happening for the second quarter and beyond? As long as we see the achievement of the Q1, just like last year, in a market like Russia and Turkey, the total industry volume has been quite steady and holding on. For Russia, just like last fiscal year, the illicit is not increasing. It's actually coming down. In Turkey, from the perspective of affordability, tobacco products are, among all the consumables, quite affordable. That environment has been continuing on. As we speak, the sign of slowing down is not being seen. The steady total demand is still continuing since last fiscal year. After Q2, whether that is going to be happening on a steady basis, right now, we do not see any negative sign of slowing down, is the best I can say. Okay. Thank you. Thank you, Ms. Miyake. Now, I'd like to take the next question. Mr. Miyazaki from Goldman Sachs, please. I'm Miyazaki of Goldman Sachs. The Q2 and beyond, I'd like to know those situations after Q1, the cost and also volume. You have explained already. Talking about the pricing in Q1, there was the increase of JPY 82 billion on year. Q2 onward, can we expect to see the similar level of the profit growth? Also, in April and onward, there was some system issue that has delayed the supply of the product. Is it one-off factor in Japan, and we don't have to be so concerned for that? These IT system troubles might be happening globally, and can we expect such a negative impact globally? I would like to have a confirmation on this point. Also, currency, there is some part which we cannot see clearly, at least in April and May. Were there any adverse impacts or negative risks happening in these two months? What is the trend for Q2 and onward? The question, Q2 and onward, the pricing, and also the delay, will be covered by Kato. For pricing, especially Q2 onward, in Q1, we had a very strong impact of the pricing, and that will be mostly sustained for the full year. Also, Q2 onward, there are some technical matters. Hyperinflation adjustment is happening in Q2 and onward, and that will be duly reflected. Especially in Iran, Ethiopia, and Turkey, in those hyperinflation markets, when we look at the current competitive environment and effects, we took our pricing, and we continue to do so, monitoring all of them. The impact is going to be more visible going forward. In Japan, there was the IT system which caused the delay of the delivery. The size of the impact out of that issue, first of all, the delay of the delivery, we are sorry for that. I'd like to apologize for that incident. The financial impact out of that is now scrutinized, and we're going to disclose that in due course. As the incident, whether that is Japan only or is it going to be a global matter, this is a Japan unique issue. Therefore, we do not expect to see the system error or the IT system trouble globally, or the delay of the delivery will not be happening on the global basis. About the effects, Furukawa will comment on that. Thank you for that question. For the currency impact, the various currencies are changing, especially the appreciation of the yen is more prominent recently. For example, based on the dollar as the key currency, yen and dollar, the yen is being appreciated now. On the contrary, the local currency and the dollar, if they are stable, since we do have the high exposure overseas business, we are going to have the negative impact of the dollar yen. Besides Japan, we have the operation in other countries. By country, the currency exposure is varied. Therefore, we need to be mindful of which currency the yen is appreciated. Also, the currency sensitivity, as we have been saying before, when the rule will change by 1%, the dollar then toward yen, then there will be the 2 or 3 billion change. That is because there is a reason why we are very watchful for the rule development. However, of course, the currency volatility has been more prominent recently. Our assumed rate and also the impact for the full year, we need to make the update if that is necessary. Thank you. Thank you very much. Mr. Miyazaki, thank you for your question. The next question comes from SMBC Nikko, Mr. Furuta. Mr. Furuta, over to you. This is Furuta of SMBC Nikko. Thank you. My question is about your policy about the dividend hike. Against the original plan, you have a positive impact coming from the effects. The performance is also good. When the original plan was made, you had the Canadian litigation, which is not going to hit the result for the FY 2025, meaning that you probably have a sufficient level of cash. Although the size is not that big, you have a disposal gain coming from the Torii Pharmaceutical. Of course, you have to work through the policy you have for the dividend. However, any cushion or any potential for hiking the dividend itself? That's my question. The question is about whether there is a leeway for the company to think about the possibility of the dividend hike that will be taken by Furukawa. This is Furukawa speaking. Thank you for your question. This time, when we look at the achievement of the Q1 results, which was just announced, the source of the dividend, the payout ratio of 75% that is coming from the outlook of the guidance, and that's coming from the effects and, of course, the macro, and they are highly volatile, as you see, in the macro's some factors, and also the total demand in each market, and also some impact to hit our business itself. They are all uncertain. Based upon those uncertainties, of course, the impact on our business has to be considered, and the impact on our financial status has to also be scrutinized from time to time. As necessary, we need to update the performance. That's going to be done after the second quarter or in the second quarter and beyond. As Furukawa just mentioned, when it comes to making the decision of the dividend, we are just looking at the 75% as the level to look at. That will be just looking at the net profit that we generate. Of course, on a single year, a profit level is covering only for a 12-month basis, but that is going to probably harvest the result coming from the past investment and also the investment contribution. From the mid to long-term basis perspective, we think we'll be able to incorporate the business situation that is going to be reflecting how much we'll be able to return. Assuming that the net profit is going to be moving, which is going to be the basis for our payout or the return to shareholders, if that is going to be changing our business performance or the other business trend, that is going to be leading the changes in the trend itself for our performance. That could be changing our business profit or the trend and the trajectory going forward after the second quarter and so on. We think we will be able to look at what we will be able to do to change the dividend level itself. Okay. Thank you very much. As was mentioned, I think by looking at the performance, I just understood that you do not have any potential risks that are emerging in reality after the second quarter and beyond, right? The effects and the macro trend, we think we need to monitor very closely. As time goes on, we want to just update our performance. Then based upon that, we need to work upon the guidance of the current fiscal year. That is going to be probably explained after the second quarter. Thank you so much. Thank you, Mr. Furuta. We are running out of time, so we'd like to take the last question. Mr. Igarashi from Daiwa Securities, please. Thank you. I'm Igarashi of Daiwa Securities. Thank you for taking my question. I'd like to ask about the Ploom share and also your expectation for share. You have shown the slide nine, and the share gain has been very solid. My question is, you have announced the transfer of the pharmaceutical business and the Torii Pharmaceutical, and also a business portfolio remains unchanged is your announcement, but you are going to have the big decision, and also you are going to put more effort for the remaining businesses. You are going to have the announcement of the new product as well. In the mid 10% line by 2028, will you be able to upload that timing and also what is the potential expectation? For tobacco business, the view for the Ploom share and also expectation. First, I'll take that question. Thank you, Mr. Igarashi. For Ploom, yes, as you have observed in each market, especially in Japan, our share gain has been very solid. As you already are aware of, 2028 is a target year, and for that midterm, we are making steady progress toward that target year in terms of the share gain. As you have mentioned also, we are going to have the new device as a new product launch. We have been progressing on track. Going forward in the next few years, we would like to proceed smoothly. Currently, for the expectation for the midterm, we are going to fulfill the plan as we have planned. What is most important for us is this year and going forward, we are going to have the new device launch. Also, there will be the transition happening from the current product, and we are going to implement that shift as we have planned. When we ensure that shift next year and onward, rather than this year, we are going to have the additional boost. We would like to consider the measures to achieve that. If we can find any areas that we need to have the additional focus, we would like to add focus for those areas as well. Currently, let me reiterate the midterm plan. We are going to achieve that target as scheduled. In order to achieve that, of course, we need to have the confidence, and we do have the confidence with the new product, new device. At the end of May, we are going to make an announcement for detail. Our confidence level can be checked at that opportunity. We are going to have the further feedback, the positive feedback from the consumers. Thank you. That's very clear. Thank you very much. Also, I'm looking forward to have the new product. Thank you. Thank you, Mr. Igarashi. With this, we would like to close the Q&A session. With this, I would like to close the web meeting of the earnings briefing at the first quarter of 2025. Thank you very much for joining us today.